PubRank

Raoul Poupon

Author PubWeight™ 103.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Primary biliary cirrhosis. Hepatology 2009 5.35
2 Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2006 3.57
3 Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009 3.12
4 Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004 2.49
5 Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002 2.38
6 Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008 2.36
7 Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006 2.21
8 Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2008 2.19
9 Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2012 2.17
10 Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol 2007 2.08
11 A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007 1.96
12 Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012 1.92
13 Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005 1.90
14 Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol 2005 1.88
15 Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005 1.85
16 Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011 1.82
17 Bile salts control the antimicrobial peptide cathelicidin through nuclear receptors in the human biliary epithelium. Gastroenterology 2008 1.73
18 Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010 1.70
19 Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003 1.68
20 The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005 1.67
21 Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations. Virchows Arch 2012 1.63
22 Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J Hepatol 2002 1.59
23 Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007 1.58
24 The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 2003 1.57
25 Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002 1.56
26 Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin? J Hepatol 2009 1.48
27 Significance of antibodies to soluble liver antigen/liver pancreas: a large French study. Liver Int 2009 1.41
28 Need to strictly define hepatitis B virus immunotolerant patients to avoid unnecessary liver biopsy. Gastroenterology 2008 1.40
29 Chronic liver injury during obstructive sleep apnea. Hepatology 2005 1.39
30 Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 2006 1.32
31 Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003 1.26
32 PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006 1.21
33 Quality of life in patients with primary biliary cirrhosis. Hepatology 2004 1.20
34 ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology 2003 1.18
35 Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis 2007 1.18
36 Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002 1.13
37 Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome. Clin Gastroenterol Hepatol 2007 1.05
38 Protoporphyrin retention in hepatocytes and Kupffer cells prevents sclerosing cholangitis in erythropoietic protoporphyria mouse model. Gastroenterology 2011 1.03
39 Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol 2010 1.01
40 Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008 0.96
41 Erythromycin infusion prior to endoscopy for acute upper gastrointestinal bleeding: a randomized, controlled, double-blind trial. Am J Gastroenterol 2006 0.96
42 Novel mutations in the Dubin-Johnson syndrome gene ABCC2/MRP2 and associated biochemical changes. Ann Clin Biochem 2012 0.92
43 [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. Gastroenterol Clin Biol 2005 0.90
44 Hepatocyte growth factor and c-Met inhibition by hepatic cell hypoxia: a potential mechanism for liver regeneration failure in experimental cirrhosis. Am J Pathol 2002 0.90
45 Genetic and acquired thrombotic factors in chronic hepatitis C. Am J Gastroenterol 2004 0.88
46 Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study. Hepatology 2009 0.87
47 Association between ABO blood group and fibrosis severity in chronic hepatitis C infection. Dig Dis Sci 2006 0.87
48 Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003 0.87
49 Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis. J Hepatol 2011 0.86
50 Factor V Leiden as a risk factor for cirrhosis in chronic hepatitis C. Hepatology 2004 0.86
51 Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease. Joint Bone Spine 2002 0.86
52 Percutaneous acetic acid injection for hepatocellular carcinoma: using CT fluoroscopy to evaluate distribution of acetic acid mixed with an iodinated contrast agent. AJR Am J Roentgenol 2003 0.85
53 Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int 2004 0.85
54 Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol 2005 0.84
55 Identification of a novel 974C-->G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids. Am J Gastroenterol 2006 0.84
56 ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology 2004 0.84
57 Prolonged cholestasis associated with short-term use of celecoxib. Gastroenterol Clin Biol 2005 0.82
58 Bile salts potentiate adenylyl cyclase activity and cAMP-regulated secretion in human gallbladder epithelium. Am J Physiol Gastrointest Liver Physiol 2002 0.82
59 Intrahepatic cholestasis of pregnancy: from bedside to bench to bedside. Liver Int 2005 0.81
60 Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom. Hepatology 2007 0.81
61 Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. Eur J Endocrinol 2007 0.81
62 Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study. Eur J Gastroenterol Hepatol 2010 0.80
63 Herpes simplex esophagitis in patients with liver disease. Dig Dis Sci 2002 0.80
64 Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther 2002 0.79
65 Role of nuclear receptors in the biliary epithelium. Dig Dis 2011 0.78
66 Cystic fibrosis transmembrane conductance regulator (CFTR) gene defects in patients with primary sclerosing cholangitis. J Hepatol 2002 0.78
67 Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis. Dig Dis 2015 0.77
68 Immune response to lipopolysaccharide in primary biliary cirrhosis and autoimmune diseases. J Autoimmun 2004 0.77
69 Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroenterol Clin Biol 2006 0.77
70 [Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma]. Gastroenterol Clin Biol 2006 0.76
71 Treatment of small hepatocellular carcinoma with acetic acid percutaneous injection. Gastroenterol Clin Biol 2005 0.76
72 [Fatal Dieulafoy's type ulcer in a case of gastric AL-amyloidosis]. Ann Pathol 2004 0.76
73 Promoter polymorphism of the CD14 endotoxin receptor gene and primary biliary cirrhosis. Hepatology 2002 0.76
74 Trials in primary biliary cirrhosis: need for the right drugs at the right time. Hepatology 2004 0.76
75 Elastography-based assessment of primary biliary cirrhosis staging. Dig Liver Dis 2011 0.76
76 Cholestasis and failure of interferon-alpha treatment. Hepatology 2004 0.75
77 Ursodeoxycholic acid and primary biliary cirrhosis with features of autoimmune hepatitis. Hepatology 2002 0.75
78 Treatment with immunosuppressives in patients with primary biliary cirrhosis who fail to respond to ursodiol. Hepatology 2009 0.75
79 Combination therapy of chronic viral hepatitis B with lamivudine and interferon: better than what? J Hepatol 2002 0.75
80 Hepatobiliary anomalies associated with ABCB4/MDR3 deficiency in adults: a pictorial essay. Insights Imaging 2013 0.75
81 Targeting farnesoid x receptor in hepatic and biliary inflammatory diseases. Gastroenterology 2009 0.75
82 [The molecular genetics of hematochromatosis]. Gastroenterol Clin Biol 2002 0.75
83 [Risks and precautions for the use of lamivudine in patients with chronic hepatitis B virus infection]. Gastroenterol Clin Biol 2002 0.75
84 Fulminant hepatitis possibly related to pizotifen therapy. Ann Pharmacother 2010 0.75
85 [Hepatobiliary transporters: from genomics to diseases]. Gastroenterol Clin Biol 2004 0.75
86 [PET and digestive cancers]. Presse Med 2007 0.75
87 [Interview: questions to Professor Raoul Poupon]. Gastroenterol Clin Biol 2003 0.75